C12N 2310/533
Having a mismatch or nick in at least one of the strands
Official title: having a mismatch or nick in at least one of the strands
C12N2310/533 (Having a mismatch or nick in at least one of the strands) appears on 171 US grants and 320 published applications in this corpus.
Search patents in C12N- Granted patents
- 171
- Published applications
- 320
- Assignees
- 118
- Inventors
- 391
- Latest grant
- 21 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2005 | 0 | 1 |
| 2006 | 0 | 2 |
| 2007 | 0 | 3 |
| 2008 | 0 | 3 |
| 2009 | 0 | 8 |
| 2010 | 1 | 15 |
| 2011 | 6 | 13 |
| 2012 | 8 | 8 |
| 2013 | 7 | 18 |
| 2014 | 8 | 19 |
| 2015 | 15 | 34 |
| 2016 | 13 | 25 |
| 2017 | 14 | 16 |
| 2018 | 10 | 12 |
| 2019 | 15 | 13 |
| 2020 | 16 | 18 |
| 2021 | 5 | 20 |
| 2022 | 12 | 27 |
| 2023 | 20 | 18 |
| 2024 | 8 | 26 |
| 2025 | 7 | 11 |
| 2026 | 6 | 10 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods of nucleic acid-targeting nucleic acids21 Jul 2026US 12,686,865 B2Caribou Biosciences, Inc.
- Targeted RNA editing16 Jun 2026US 12,655,423 B2ProQR Therapeutics II B.V.
- Synthetic production of single-stranded adeno associated viral DNA vectors17 Mar 2026US 12,577,573 B2Generation Bio Co.
- Compositions and methods for inhibiting GYS2 expression27 Jan 2026US 12,534,730 B2Novo Nordisk A/S
- Double-stranded nucleic acid inhibitor molecules with shortened sense strands20 Jan 2026US 12,529,053 B2Novo Nordisk A/S
- Crispr systems with engineered dual guide nucleic acids6 Aug 2026US 2026/0226509 A1Celyntra Therapeutics SA
- Dux4-targeting engineered guide rnas and polynucleotides23 Jul 2026US 2026/0209755 A1Shape Therapeutics Inc.
- Compositions and methods comprising programmable snrnas for rna editing28 May 2026US 2026/0144893 A1Regeneron Pharmaceuticals, Inc.
- Rna molecules7 May 2026US 2026/0125676 A1Commonwealth Scientific and Industrial Research Organisation
- Chemical modifications of small interfering rna with minimal fluorine content7 May 2026US 2026/0125682 A1Novo Nordisk A/S
Most cited
By later US patents
- Methods and compositions involving miRNA and miRNA inhibitor molecules171US 9,506,061 B2Asuragen, Inc. · 2016
- Extended dicer substrate agents and methods for the specific inhibition of gene expression113US 8,513,207 B2Dicerna Pharmaceuticals, Inc. · 2013
- Single stranded extended dicer substrate agents and methods for the specific inhibition of gene expression95US 8,349,809 B2Dicerna Pharmaceuticals, Inc. · 2013
- Therapeutic compositions76US 8,110,674 B2Alnylam Pharmaceuticals, Inc. · 2012
- RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)70US 9,181,551 B2Sirna Therapeutics, Inc. · 2015